OpenURL Connection Search

Select item for more details and to access through your institution.

A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection.
Published in:
Genes & Immunity, 2002, v. 3, n. 6, p. 345, doi. 10.1038/sj.gene.6363880
By:
- Reynolds, W.F.;
- Patel, K.;
- Pianko, S.;
- Blatt, L.M.;
- Nicholas, J.J.;
- McHutchison, J.G.
Publication type:
Article
Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.
Published in:
Alimentary Pharmacology & Therapeutics, 2003, v. 17, n. 9, p. 1197, doi. 10.1046/j.1365-2036.2003.01544.x
By:
- Sievert, W.;
- Batey, R.;
- Mollison, L.;
- Pianko, S.;
- Mcdonald, J.;
- Marinos, G.;
- Reed, W.;
- Warner, S.;
- Bowden, S.;
- De Solom, R.;
- Bhathal, P.
Publication type:
Article
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.
Published in:
Journal of Viral Hepatitis, 2013, v. 20, n. 4, p. e115, doi. 10.1111/jvh.12020
By:
- Foster, G. R.;
- Zeuzem, S.;
- Pianko, S.;
- Sarin, S. K.;
- Piratvisuth, T.;
- Shah, S.;
- Andreone, P.;
- Sood, A.;
- Chuang, W.‐L.;
- Lee, C.‐M.;
- George, J.;
- Gould, M.;
- Flisiak, R.;
- Jacobson, I. M.;
- Komolmit, P.;
- Thongsawat, S.;
- Tanwandee, T.;
- Rasenack, J.;
- Sola, R.;
- Messina, I.
Publication type:
Article
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Published in:
Journal of Viral Hepatitis, 2012, v. 19, n. 9, p. 623, doi. 10.1111/j.1365-2893.2012.01586.x
By:
- Pianko, S.;
- Zeuzem, S.;
- Chuang, W.-L.;
- Foster, G. R.;
- Sarin, S. K.;
- Flisiak, R.;
- Lee, C.-M.;
- Andreone, P.;
- Piratvisuth, T.;
- Shah, S.;
- Sood, A.;
- George, J.;
- Gould, M.;
- Komolmit, P.;
- Thongsawat, S.;
- Tanwandee, T.;
- Rasenack, J.;
- Li, Y.;
- Pang, M.;
- Yin, Y.
Publication type:
Article
Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.
Published in:
Journal of Viral Hepatitis, 2006, v. 13, n. 5, p. 311, doi. 10.1111/j.1365-2893.2005.00685.x
By:
- Desmond, C. P.;
- Roberts, S. K.;
- Dudley, F.;
- Mitchell, J.;
- Day, C.;
- Nguyen, S.;
- Pianko, S.
Publication type:
Article
The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.
Published in:
Journal of Viral Hepatitis, 2003, v. 10, n. 1, p. 16, doi. 10.1046/j.1365-2893.2003.00387.x
By:
- Myers, R. P.;
- Patel, K.;
- Pianko, S.;
- Poynard, T.;
- McHutchison, J. G.
Publication type:
Article
Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection.
Published in:
Journal of Viral Hepatitis, 2001, v. 8, n. 6, p. 406, doi. 10.1046/j.1365-2893.2001.00316.x
By:
- Pianko, S.;
- Patella, S.;
- Ostapowicz, G.;
- Desmond, P.;
- Sievert, W.
Publication type:
Article

Found: 7

A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection.

Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting.

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C.

Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection.